Barton J C, Conrad M E
Ann Intern Med. 1979 Feb;90(2):188-90. doi: 10.7326/0003-4819-90-2-188.
Of 50 consecutive patients admitted with acute myelogenous leukemia, 30 developed complete remissions on antileukemic therapy. Nineteen of the 30 repeatedly had elevated serum glutamic oxalacetic transaminase (SGOT) concentrations 3 to 14 weeks after the start of therapy. Patients with SGOT elevations had a significantly greater chance of remission and a longer survival (76 +/- 11 weeks) than those with normal SGOT levels (39 +/- 5 weeks), suggesting that hepatitis may have a beneficial effect in acute myelogenous leukemia. The hepatitis was mild in all patients. Review of patients at this institution alive 2 years after the diagnosis of acute myelogenous leukemia showed that they repeatedly had elevated SGOT levels. We believe that most had non-A, non-B post-transfusion hepatitis, which may have a beneficial effect on the leukemia or serve as an indicator of patients who have greater immunocompetence and thus a better prognosis.
在连续收治的50例急性髓性白血病患者中，30例在接受抗白血病治疗后实现完全缓解。30例中有19例在治疗开始后3至14周血清谷草转氨酶（SGOT）浓度反复升高。SGOT升高的患者缓解几率显著更高，生存期（76±11周）也比SGOT水平正常的患者（39±5周）更长，这表明肝炎可能对急性髓性白血病有有益作用。所有患者的肝炎均为轻度。对本机构中诊断为急性髓性白血病2年后仍存活的患者进行回顾发现，他们的SGOT水平反复升高。我们认为大多数患者患有非甲非乙型输血后肝炎，这可能对白血病有有益作用，或者作为免疫功能更强、预后更好的患者的一个指标。
